ND-630

an acetyl-CoA carboxylase inhibitor; structure in first source

Also Known As:

1,4-dihydro-1-(2-(2-methoxyphenyl)-2-((tetrahydro-2H-pyran-4-yl)oxy)ethyl)-alpha,alpha,5-trimethyl-6-(2-oxazolyl)-2,4-dioxothieno(2,3-d)pyrimidine-3(2H)-acetic acid

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - ND-630: 1
  - Thiophenes: 257
    - ND-630: 1
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiophenes: 257
    - ND-630: 1

Experts

1.	Bhat, Sathesh: 1 article (03/2016)
2.	Greenwood, Jeremy: 1 article (03/2016)
3.	Harriman, Geraldine: 1 article (03/2016)
4.	Harwood, H James: 1 article (03/2016)
5.	Huang, Xinyi: 1 article (03/2016)
6.	Kapeller, Rosana: 1 article (03/2016)
7.	Paul, Debamita: 1 article (03/2016)
8.	Saha, Asish K: 1 article (03/2016)
9.	Tong, Liang: 1 article (03/2016)
10.	Wang, Ruiying: 1 article (03/2016)

Related Diseases

1.	Dyslipidemias (Dyslipidemia) 03/29/2016 - "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats." 03/29/2016 - "When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. "
2.	Weight Gain 03/29/2016 - "When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. "
3.	Obesity 03/29/2016 - "When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. "
4.	Insulin Resistance 03/29/2016 - "Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats." 03/29/2016 - "When administered chronically to rats with diet-induced obesity, ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. "

Related Drugs and Biologics

1.	Acetyl-CoA Carboxylase